Objectives We undertook a meta-analysis to assess outcomes for drug-eluting stents (DES) and bare-metal stents (BMS) in percutaneous coronary intervention for unprotected left main coronary artery (ULMCA) stenosis.
Unprotected left main coronary artery stenosis (LMCA) is associated with poor clinical outcomes. Studies have shown improved long-term outcomes in those who undergo surgical revascularization as compared to optimal medical therapy alone (1, 2) . This is the basis for the American College of Cardiology/American Heart Association class I recommendation for coronary artery bypass graft surgery (CABG) in patients with Ն50% left main stenosis (3) .
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Early percutaneous attempts at revascularization with balloon-only angioplasty were associated with suboptimal clinical outcomes (4) . This led to an American College of Cardiology/American Heart Association Class III (contraindicated) guidelines recommendation for percutaneous coronary intervention (PCI) in CABG-eligible patients (5) . The subsequent advent of coronary stents, which reduced periprocedural risks and improved clinical outcomes, renewed interest in unprotected LMCA PCI. This interest was further fueled by the subsequent introduction of drug-eluting stents (DES), which led to substantially lower rates of restenosis in coronary lesions (6, 7) . Based on improved clinical outcomes, the most recent American College of Cardiology/American Heart Association guidelines have given unprotected LMCA PCI a class IIb recommendation (8) .
However, there remains some clinical uncertainty over the ideal stent type for unprotected LMCA PCI. The use of DES in the left main position is considered an off-label application; previous studies have identified increased adverse events for such off-label applications (9) . Additionally, although the reduction in restenosis seen with DES use is particularly attractive for unprotected LMCA PCI, the large caliber of most left main arteries could attenuate this benefit. Finally, concern exists over potentially increased rates of late stent thrombosis with DES, which has serious implications in unprotected LMCA PCI (10) .
We performed a meta-analysis of the current literature to assess outcomes of PCI in unprotected LMCA and to compare the relative performance of DES and bare-metal stents (BMS) in this application.
Methods
Search strategy. PubMed, clinicaltrials.gov, and BioMed Central databases were searched from January 2000 to September 2009; there were no language restrictions. Search terms included "left main," "coronary," "intervention," and "stenting." Citations were screened and evaluated using the established inclusion/exclusion criteria at the abstract level by 2 operators (S.P. and N.B.), and relevant studies were retrieved as full manuscripts. Inclusion criteria were: 1) involving unprotected left main disease; 2) involving BMS or DES; and 3) involving at least 20 patients in the overall study cohort. Exclusion criteria were defined as: 1) unpublished studies; 2) abstract only; 3) angioplasty without stenting; 4) ST-segment elevation myocardial infarction; 5) cardiogenic shock; 6) experimental devices; 7) non-English studies; and 8) studies not reporting relevant clinical outcomes. Data regarding patient demographics and clinical outcomes were then entered into a database. End points. The co-primary end points were mortality, myocardial infarction (MI), target vessel/target lesion revascularization (TVR/TLR), and major adverse cardiac events (MACE), which were defined as mortality, MI, and TVR/ TLR. These end points were reported for the following time periods post-PCI: 6 to 12 months, 2 years, and 3 years. Data for all end points at each time period were not available for every study. Statistical analysis. Crude event rates were reported for mortality, MI, and TVR/TLR for both DES and BMS. Because these estimates were based, in part, on studies for which a causal link between stent type and outcome was not established, direct comparison of rates is not appropriate, and rates can only be seen as descriptive in nature. Subsequent comparative analysis was performed evaluating studies that provided adjusted outcomes on relevant end points or were randomized according to stent types; odds ratios (OR) were reported for this analysis. When both hazard ratios (HR) and OR were reported as end points across trials, they were combined, assuming that the follow-up was fairly complete (and thus the HR would be similar to the expected OR). Similarly, Kaplan-Meier rates and percentages were combined when 1 of the 2 was not available for an end point. Several end points did not meet the assumption of homogeneity of rates across studies, and thus random effects modeling techniques were used to combine rates and calculate confidence intervals. Comprehensive Meta Analysis software, version 2.2.048 (Biostat Inc., Englewood, New Jersey), was used for all analyses (11) .
Results
Database searches retrieved an initial 838 studies, of which 75 were deemed relevant; 31 of these studies were eventually excluded Patient demographics in the group undergoing BMS placement were generally similar to those undergoing DES placement ( Table 2 ). There was incomplete reporting of baseline demographics across studies. Medication profiles, including duration of antiplatelet drug therapy, were inconsistently reported.
Estimates of rates for mortality, MI, and TVR/TLR at each of the 3 recorded time points are displayed in Table 3 . The rates of events are numerically higher for patients treated with BMS for most end points, at most time points. However, without adjustment, the significance and/or relevance of the differences noted cannot be fully determined. As expected, the overall rates of events are higher in patients undergoing unprotected LMCA PCI than in conventional PCI patients.
Subsequent analysis was performed on those studies comparing DES and BMS and providing either adjusted event rates, or randomization according to stent type. Of the 12 comparative studies, 9 studies (33,69 -72,74,77-79) reported relevant end points, consisting of 5,081 patients (Table 4) . Most utilized propensity scoring for adjustment. Comparative event estimates for DES versus BMS were calculated (Table 5) BMS ϭ bare-metal stent(s); CABG ϭ coronary artery bypass graft; DES ϭ drug-eluting stent(s); PCI ϭ percutaneous coronary intervention. 
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Discussion
Percutaneous coronary intervention is increasingly being performed for lesions previously considered contraindicated, such as unprotected LMCA. Given the lower rates of restenosis reported with DES in PCI of standard coronary lesions, there has been a trend toward their use in unprotected LMCA PCI. However, the superiority of DES over BMS for unprotected LMCA has not been clearly established. We reviewed the literature on unprotected LMCA PCI to compare outcomes between DES and BMS. We identified 44 studies involving PCI for unprotected LMCA as a source for crude event rates. Crude event rates were lower for DES than BMS for mortality, TVR/TLR, and MACE at 6 to 12 months, 2 years, and 3 years, but appeared equivalent for MI at these same time points. However, these rates are unadjusted, rendering them prone to selection bias and confounding.
To address this, we performed a subsequent analysis involving studies that provided adjusted event rates or randomized patients according to stent type (DES vs. 
BMS).
Although event rates at 6 to 12 months favored DES, the sample size was small, involving predominantly 1 study (70) . At 2 and 3 years post-PCI, the sample size was larger, and improved outcomes with DES over BMS were observed for mortality, MI, TVR/TLR, and MACE. Statistically significant differences were observed in most cases. Although the finding of lower TVR/TLR rates is consistent with the known performance of DES, no study to date has shown a consistent mortality benefit with DES over BMS in unprotected LMCA PCI. The reason for the lower mortality rate in the DES group seen in our metaanalysis is unclear. It may be that DES, with known lower rates of restenosis, provides a true advantage over BMS. In the critical left main position, a small or moderate degree of restenosis could theoretically precipitate critical ischemia. Alternatively, this finding could be due to methodological issues. Selection bias may have favored DES: patients with fewer medical comorbidities may have preferentially undergone DES placement. A review of overall patient demographics in our analysis does not support this, as similar rates of cardiac risk factors were found between both groups (Table 2 ). An alternative explanation may relate to a procedural learning curve, as operators may have become more technically proficient at unprotected LMCA PCI by the time DES were favored. Finally, as medication profiles at baseline and follow-up were not consistently reported, it is possible that the benefit seen with DES could be due, in part, to a longer duration of dual antiplatelet drug therapy as compared with BMS. Similarly, patients deemed to be poor candidates for long-term dual or triple antiplatelet therapy may have been denied treatment with DES.
A recent meta-analysis of patients undergoing DES for unprotected LMCA by Biondi-Zoccai et al. (87) noted similar findings, reporting an adjusted OR of 0.34 for both MACE and TVR, favoring DES over BMS. This metaanalysis was performed through 2006 and included far fewer patients than our analysis (206 DES patients, 190 BMS patients). Since our analysis was performed, Buszman et al. (88) have reported on the long-term follow-up of a group of 252 patients from the LE MANS (Left Main Coronary Artery Stenting) registry. Their results mirror ours. Unmatched analysis showed a significantly lower rate of major adverse cardiovascular or cerebral events with DES as compared with BMS at 4-year follow-up (14.9% vs. 25.9%, p ϭ 0.039); subsequent propensity matched analysis showed similar results. Buszman et al. (88) noted that mortality rates favored DES, although this did not reach statistical significance (9.6% vs. 13.3%, p ϭ NS). In a subgroup of patients with distal unprotected LMCA, however, DES, when compared with BMS, was associated with a statistically significant lower mortality rate (p ϭ 0.03). Results from the left main subset of the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial (89) were presented at Transcatheter Cardiovascular Therapeutics 2008 conference. Reported 12-month DES event rates were similar to our cumulative crude estimates, with a rate of 4.2% for n refers to the number of patients within the studies who contributed to the estimate of interest. Odds ratios (ORs) are reported with 95% CIs.
Abbreviations as in Tables 1 to 4 . (91); the meta-analytical approach with observational data is even more fraught with limitations (92) . The inclusion of only published studies makes our analysis prone to publication bias. Our results, particularly the crude event rates, are prone to confounding and selection bias and thus direct comparison of these overall rates was not performed. We did not have data for all studies at each time period; therefore, this limits comparison of rates across time within a specific end point. Finally, we were unable to control for the specific type of DES or BMS used, as some studies suggest heterogeneous outcomes within the stent types.
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Conclusions
The results of this meta-analysis suggest that DES is associated with favorable outcomes as compared with BMS in unprotected LMCA PCI. The improved outcomes observed when DES is compared with BMS support a continued re-evaluation of the role of PCI for the treatment of unprotected LMCA. 
